semaj83/ctmatch_classification huggingface dataset:
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 25.0-999.0,  Cervical Squamous Cell Carcinoma In Situ Vulvar High Grade Squamous Intraepithelial Lesion Histologically confirmed squamous CIN 3, or VIN 3 (usual type only) The subject is either surgically sterile, postmenopausal, or agrees to practice an effective method of birth control as determined by the investigator (to be continued throughout the study period), except that subjects with CIN 3 are not permitted to use a cervical cap or diaphragm for contraception White blood cell > 2,500/ mcL (> 2.5 x 10^9/L) Absolute neutrophil count > 1,000/ microliter (> 1 x 10^9/L) Platelet count > 75,000/ mcL (> 75 x 10^9/L) Hemoglobin >= 8 g/dL (>= 80 g/L) (subjects who have received a transfusion or erythropoietin up to one week prior to receiving the first dose of cyclophosphamide are eligible for the study) International normalized ration (INR) or prothrombin time (PT) < 1.5 x ULN (upper limit of normal) Activated partial thromboplastin time (aPTT) < 1.5 x ULN Serum creatinine < 1.5 x ULN Total bilirubin < 2.0 x ULN unless thought to be related to inherited bilirubin conjugation disorder (ie Gilbert?s disease)  For subjects with cervical dysplasia: evidence of atypical glandular cells or adenocarcinoma in situ (ACIS) based on cervical cytology, colposcopy or biopsy For subjects with either cervical or vulvar squamous dysplasia: evidence of microinvasive squamous carcinoma based on cytology, colposcopy or biopsy Pregnancy or lactation Allergy to ciprofloxacin or other quinolones (because ciprofloxacin is used in preparation of IRX-2) Allergy to indomethacin (a necessary component of the regimen) or to acetylsalicylic acid (aspirin) due to likely allergy cross-reaction Aldara (imiquimod) for the topical treatment of lower genital tract warts or dysplasia within 3 months of study enrollment Known to be positive for human immunodeficiency virus-1 (HIV-1) antibody, human immunodeficiency virus-2 (HIV-2) antibody, hepatitis B surface antigen, or hepatitis C virus antibody Known to have other immunodeficiency diseases, including cellular immunodeficiencies, hypogammaglobulinemia, or dysgammaglobulinemia Immunotherapy (eg, interferons, tumor necrosis factor, interleukins) or biological response modifiers (granulocyte-macrophage colony-stimulating factor, granulocyte colony-stimulating factor, macrophage colony-stimulating factor) or any investigational drug within 3 months of study enrollment Concurrent treatment with systemic corticosteroids at a dose of >= 5 mg/day of prednisone (or equivalent)
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 19.0-68.0,  Cervical Intraepithelial Neoplasia Cervix Neoplasm Indication of cervical conization  We excluded patients who were not treated by our department physicians or if the patient did not return for follow-up
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Functional Dyspepsia Three days before the measurement: no smoking and drinking alcohol hours before the measurement: no drinking and eating  symptoms or history of gastrointestinal disease first degree relatives with celiac disease diabetes mellitus allergy/atopy (eczema, asthma, allergic rhinoconjunctivitis) coagulation disorders/anticoagulant therapy first degree relatives with Crohn's disease or type I diabetes mellitus intake of antihistamines, ketotifen, cromoglycate, acetylsalicylates, NSAIDs, anticholinergics, theophylline, β2-agonists, codeine or opioid derivatives for at least 2 weeks prior to the gastroscopy Intake of steroid or immunosuppressive drugs in the last 6 months
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Adult Spinal Deformity All patients diagnosed with ASD, fulfilling the following radiographic based on whole spine lateral film are eligible for recruitment SVA bigger than 47mm Pelvic tilt (PT) bigger than 22deg Pelvic incidence (PI) lumbar lordosis (LL) bigger than 11deg  If the aetiology of the ASD of the patient is neuromuscular origin other pathologies that may affect their gait such as previous trauma or surgeries to the pelvis or the lower limbs and joint replacements inability to walk without aids for short distances
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 20.0-65.0,  Healthy Are overtly healthy males or females, as determined by medical history and physical examination Women not of child-bearing potential due to surgical sterilization confirmed by medical history or menopause Are first-generation Japanese or non-Japanese. First-generation Japanese is defined as the participant, the participant's biological parents, and all of the participant's grandparents are of exclusive Japanese descent and have been born in Japan Have a body weight of more than 54 kilograms (kg)  Currently enrolled in a clinical study or have participated in a study within the past 3 months Have an abnormality in the 12-lead electrocardiogram (ECG) at screening Have history of pancreatitis Have known or ongoing psychiatric disorders Have undergone bariatric surgery or have used any drugs for weight loss Have a history of alcoholism Currently smoke more than 10 cigarettes a day
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 30.0-49.0,  Human Papillomavirus Infection Cervical Cancer The District Health Management Team (DHMT), estimates that in 2011 there were 31,574 women 30-49 years of age on the Kweneng East catchment area, serviced by Scottish Livingstone Hospital and the 4 selected Health Clinics. Women will be clients of the health facility at one of the clinics (described below under recruitment), may come to the facility for cervical cancer screening after having been contacted by a community mobilizer, or women attending a community health campaign event (in the community). Participants under Research Question 1: 1022 women Participants under Research Question 2a: 24 providers and other stakeholders Participants under Research Question 2b: 27 women for in-depth interviews; 250 women for structured surveys. Service Delivery Model Age 30 to 49 years Not screened recently/never screened before, defined as No prior history of cervical cancer screening: Pap smear, VIA or HPV testing), or Prior screening, but result unknown and no treatment Prior screening occurred more than 5 years ago for HIV negative women or 3 years ago for HIV positive women HIV status is known (HIV positive result, or documented HIV negative result is less than 12 months ago) No history of prior abnormal screening or treatment/procedure on her cervix due to abnormal screening No history of cervical cancer Not currently pregnant; not less than 6 weeks postpartum  Woman does not meet the for age 29 years or younger and age 50 years or older Screened for cervical cancer in last 3 years if HIV positive, or in the last 5 years if HIV negative Had an abnormal cervical cancer screening and/ or treatment of cervix  History of cervical cancer HIV status unknown Pregnant (self-report or by pregnancy test confirmation Less than 6 weeks postpartum, prior hysterectomy Unable to participate and give informed consent Not interested in HPV self-collection Unwilling to give informed consent
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 0.5-75.0,  Human Papilloma Virus Written, informed consent obtained prior to any study-specific procedures. 2. Evidence of HPV virus activation (viral DNA) or high risk of HPV infection. 3. Not suitable for routine treatment or invalid to antiviral drugs. 4. Patients with viral disease symptoms and confirmed by biopsy, regardless of the level of virus DNA. 5. Age less than 75 years. 6. Did not use Penicillin or β-lactam antibiotics, or the lowest dose of other antibiotics. 7. Initial hematopoietic reconstitution: neutrophils (ANC) ≥ 1,000/mm^3, platelet (PLT) ≥ 1,000/mm^3. 8. Proper renal and hepatic functions (ULN denotes "upper limit of normal range"): Creatinine ≤ 2*ULN, Bilirubin ≤ 2*ULN, SGOT/ SGPT ≤ 3*ULN. 9. If HPV-CTL is not from the patient's own, then the provider of HPV-CTL needs to meet the following did not receive chemotherapy or radiotherapy within 4 weeks prior to blood collection, and did not take any steroids for the previous week, did not use Penicillin or β-lactam antibiotics, or the lowest dose of other antibiotics white blood cells ≥ 3,500 / μl, lymphocytes ≥ 750 / μl. 10. Human immunodeficiency virus (HIV) test was negative  Subject or the donor of BMT recipient infected with HCV (HCV antibody positive), HBV (HBsAg positive), HIV (HIV antibody positive), HTLV (HTLV antibody positive), Treponema pallidum antibody positive or TB culture positive. 2. Subject is albumin-intolerant. 3. Subject with life expectancy less than 8 weeks. 4. Subject participated in other investigational somatic cell therapies within past 30 days. 5. Subject with positive pregnancy test result
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 20.0-60.0,  Cervical Intraepithelial Neoplasia Grade 2/3 Diagnosis: Patients who need to do gynecological pelvic examination Age and sex: Women between the ages of 20  Women with total hysterectomy Women who have done cervical surgeries, including physiotherapy of conization, LEEP, infrared ray, and microarray Women with serious cervical contact bleeding Women who are pregnant or menstrual period before the examination Women with acute inflammation of cervix and/or vagina Women who were already diagnosed with CIN2+ Women who are taking an oral and/or injection of anti-cancer drugs
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  HPV Vaccines All providers and staff at each practice  None
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 21.0-65.0,  Human Papilloma Virus Abnormal cytology of atypical squamous cells of undetermined significance (ASCUS) on Pap smear OR Low-grade squamous intra epithelial lesions (LSIL) on Pap smear OR Positive hrHPV on routine screening (positive HPV will be assumed to be high grade)  Patients who proceed to excisional procedures (loop electrosurgical excision procedure or cold knife conization) Pregnant patients Breastfeeding patients Immunocompromised patients
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Term Labour A woman will be considered for in the study if she fulfills all of the following She has a term or near term (≥36 completed weeks) singleton gestation in a cephalic presentation and has been admitted to the Labor and Delivery Unit  She is in the latent phase of spontaneous labor, or has been admitted for induction of labor She has given her informed consent to participate as a subject She has none of the  Known major fetal malformation or chromosome abnormality Multiple gestation A condition for which cesarean will likely be carried out shortly Subject plans not to have electronic fetal monitoring Involvement in another clinical trial currently or previously in this pregnancy that, in the investigator's opinion, would affect the conduct of this study Medical or obstetric problem that would preclude the use of abdominal electrodes (e.g., skin eruptions, history of sensitivity to adhesives) Parturient is under age 18 Medical or obstetric problem that in investigator's opinion would make the patient incapable of taking part in the study Inability to understand the consent information due to medical illness or diminished intellectual capacity, or insurmountable language barrier Potential for coercion, e.g. Medical Center employees, prisoners
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 20.0-60.0,  ASC-US LSIL Women with previous abnormal Pap test results (ASCUS, LSIL) Women between the ages of 20 and 60  Hysterectomised women Women with known pregnancy Non-consenting women Women that are not able to understand and to sign the informed consent Women who diagnosed and treated for cervical cancer or other malignancies Concurrent diseases that are immunosuppressed or require the use of immune-suppressants
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Cervical Intraepithelial Neoplasia Human Papilloma Virus 65 years old; generally healthy gynecological conditions, normal sexual life; high risk HPV; Cervical biopsy CIN or no cytological changes; signed informed consent  Pregnant woman;local or systematic treatment within 3 months; Comorbidity of other severe gynecological inflammation, infection, or tumor; Comorbidity of other serious illnesses； no guarantee of timely treatment and follow-up
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervical Cancer Screening One previous routine screening Pap test showing ASC-US, HPV positive Two previous consecutive routine screening Pap tests showing ASC-US or LSIL  previous hysterectomy pregnant or considering pregnancy in the next 18 months had a previous excisional or ablative procedure of the cervix younger than 18
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 21.0-29.0,  Alcohol Drinking Alcohol Use Disorder Alcohol Intoxication Alcohol; Harmful Use Alcoholism Binge Drinking to 29 years of age currently drinks alcohol owns a smartphone  are masked from public viewing until data collection is complete. Please contact project managers.]
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Obstetric Complication Postpartum Hemorrhage Postpartum Endometritis Female Able to give consent Gestational age > 24 weeks Postpartum Placement of an IBT within the last 2 hours with plans for it to remain in situ for at least 2 hours Primary obstetrician amenable to proceeding with either method of management during the study period  Age < 18 years old IBT removed within 2 hours of placement Chorioamnionitis Insufficient documentation of demographics, delivery outcomes, or peripartum events including postpartum hemorrhage, infectious outcomes
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 30.0-999.0,  Patient Adherence In the Randomized Controlled Trial we will recruit a minimum of 4000 women, aged 30 and older living in the province of Jujuy, Argentina. are: 1. Having performed self-collection of HPV-testing. 2. Mentally competent to understand the consent form. 3. Able to communicate with study staff. 4. Being able to provide a mobile phone telephone number  Current pregnancy Women with Mental disability
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 9.0-26.0,  Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in Situ Not pregnant and 1) not a woman of childbearing potential (WOCBP), or 2) a WOCBP who has not had sex with males or has had sex with males and used effective contraception since the first day of participant's last menstrual period through Day 1 and understands and agrees that during the study she should not have sexual intercourse with males without effective contraception (the rhythm method, withdrawal, and emergency contraception are not acceptable methods per the protocol) Participant and participant's parent or guardian (participants aged 9-17 years only) provided written informed consent/assent Provided a primary and alternative telephone for follow-up purposes Extension Stage: participant was enrolled in the 9-19 years old group, received 3 doses of V501 in the Base Stage, and participant and participant's legally acceptable representative (if applicable) provided written informed consent/assent for the study extension  History of severe allergic reaction that required medical intervention Allergic to any vaccine component, including aluminum, yeast, or Benzonase® (nuclease) Known thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections Currently immunocompromised or was diagnosed as having congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), inflammatory bowel disease, or other autoimmune condition History of splenectomy Any condition which in the opinion of the investigator might interfere with the evaluation of the study objectives History of recent or ongoing alcohol or other drug abuse History of a positive test for HPV Any history of abnormal Pap test History of external genital wart, vulvar intraepithelial neoplasia (VIN), vaginal intraepithelial neoplasia (VaIN), vulvar cancer or vaginal cancer